Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Relmada Therapeutics Inc (RLMD) PT Raised to $90 at Truist Securities
July 27, 2021 10:14 AM UTCTruist Securities analyst Joon Lee raised the price target on Relmada Therapeutics Inc (NASDAQ: RLMD) to $90.00 (from $75.00) while maintaining a Buy rating.
... MoreRelmada Therapeutics (RLMD) to Resume Trading at 8:30 a.m.
July 27, 2021 8:26 AM UTCRelmada Therapeutics (NASDAQ: RLMD) to Resume Trading at 8:30 a.m.
Relmada Therapeutics (RLMD) Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
July 27, 2021 7:35 AM UTCRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3... More
Relmada Therapeutics (RLMD) Halted, News Pending
July 27, 2021 7:25 AM UTCRelmada Therapeutics (NASDAQ: RLMD) Halted, News Pending
